Pharmaceuticals, Biotechnology and Life Sciences
Britain’s biotech sector boasts the strongest new drug pipeline in Europe but industry leaders say it needs continued access to global talent, funding and regulatory clarity to thrive in the future – all of which could be jeopardized by Brexit.
Bioverativ has acquired South San Francisco-based True North Therapeutics, a privately-held, clinical-stage rare disease biotechnology company, for an upfront payment of $400 million plus assumed cash.
Emmy and Tony award-winning actress and singer, Kristin Chenoweth will kick off Allergan’s “Less Red, More You” campaign at an exclusive event in New York City.
The U.S. Food and Drug Administration on Tuesday approved Merck’s Keytruda as a first cancer treatment for any solid tumor with a specific genetic feature.
Horizon Pharma has reached an agreement to sell a European subsidiary that owns the marketing rights to Procysbi (cysteamine bitartrate) delayed-release capsules and Quinsair (levofloxacin inhalation solution) in Europe, the Middle East and Africa (EMEA) regions to Chiesi Farmaceutici S.p.A. (Chiesi) for an upfront payment of $70 million, with additional potential milestone payments based on sales targets.
Selexis SA and OSE Immunotherapeutics have signed a commercial license agreement that provides OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform.
Summit Therapeutics, the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficile infection (‘CDI’), has appointed Dr David Roblin as Chief Medical Officer, Anne Heatherington, PhD, as Head of Clinical Development and Quantitative Sciences and Dave Powell, PhD, as Head of Research.
Boehringer Ingelheim has reported new analyses that provide further evidence that adding SPIRIVA RESPIMAT improved breathing across diverse patient populations who experience uncontrolled asthma symptoms despite the use of another daily maintenance therapy in the Phase III clinical development program.
Alexion Pharmaceuticals has announced big changes to its executive leadership team. Brian Goff is joining Alexion as Chief Commercial Officer, effective June 1, 2017.
Molecular Biology 2017 aims to shed focus on the transnational nature of biotechnological research, with emphasis on both the
basic science as well as its applications in industry and academia. Latest researches, agricultural Molecular Biology, business models,
pharmaceutical Molecular Biology, medical Molecular Biology, cancer biology, immunology, genetics, protein engineering,
plant and environmental technologies, transgenic plant and crops, bio remediation, and microbial diversity research will be the subjects of discussion.